Abstract
BackgroundStimulating antitumor immunity by blocking programmed death-1 (PD-1) or its ligand (programmed death-ligand 1 (PD-L1) is a promising antitumor therapy. However, numerous patients respond poorly to PD-1/PD-L1 blockade. Unresponsiveness to...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have